The biologic DMARDs rituximab and abatacept were associated with an increased risk for incident cancers in patients with RA ...
Medpage Today on MSN7d
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular LymphomaThe combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with ...
SAN DIEGO -- Patients with mantle cell lymphoma (MCL) and undetectable minimal residual disease (uMRD) after induction ...
"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...
Despite treatment advancements with the introduction of HDMTX and rituximab, up to half of patients will have disease relapse, and 10%–15% may have primary refractory disease.
Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...
Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...
Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib in adult patients ...
With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback